AIMS: Large B cell lymphomas with MYC and BCL6/3q27 rearrangements, designated MYC/BCL6 DHL, are uncommon. Our aim was to better characterize this group of tumours. METHODS AND RESULTS: We studied the clinicopathological features and outcome of 13 patients with MYC/BCL6 DHL and compared this group to a group of 83 MYC/BCL2 DHL patients. There were eight men and five women, with a median age of 63 years. Eleven tumours were classified as diffuse large B cell lymphomas (DLBCL) and two were B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU). Immunohistochemical analysis showed that these tumours were positive for BCL6 (100%), BCL2 (eight of 10; 80%) and CD10 (eight of 10; 80%). Nine of 12 (75%) cases had a germinal centre B cell (GCB) immunophenotype; in one case data were incomplete. All patients were treated with chemotherapy. The clinicopathological features of MYC/BCL6 DHL were similar to MYC/BCL2 DHL, except that MYC/BCL6 DHL had a GCB immunophenotype less often. Patients with MYC/BCL6 DHL had a poor overall survival, similar to patients with MYC/BCL2 DHL (P = 0.32). CONCLUSIONS: MYC/BCL6 DHL is an aggressive B cell lymphoma and patients often have an aggressive clinical course and poor prognosis, similar to patients with MYC/BCL2 DHL.
AIMS: Large B cell lymphomas with MYC and BCL6/3q27 rearrangements, designated MYC/BCL6 DHL, are uncommon. Our aim was to better characterize this group of tumours. METHODS AND RESULTS: We studied the clinicopathological features and outcome of 13 patients with MYC/BCL6 DHL and compared this group to a group of 83 MYC/BCL2 DHL patients. There were eight men and five women, with a median age of 63 years. Eleven tumours were classified as diffuse large B cell lymphomas (DLBCL) and two were B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU). Immunohistochemical analysis showed that these tumours were positive for BCL6 (100%), BCL2 (eight of 10; 80%) and CD10 (eight of 10; 80%). Nine of 12 (75%) cases had a germinal centre B cell (GCB) immunophenotype; in one case data were incomplete. All patients were treated with chemotherapy. The clinicopathological features of MYC/BCL6 DHL were similar to MYC/BCL2 DHL, except that MYC/BCL6 DHL had a GCB immunophenotype less often. Patients with MYC/BCL6 DHL had a poor overall survival, similar to patients with MYC/BCL2 DHL (P = 0.32). CONCLUSIONS:MYC/BCL6 DHL is an aggressive B cell lymphoma and patients often have an aggressive clinical course and poor prognosis, similar to patients with MYC/BCL2 DHL.
Authors: Solène M Evrard; Sarah Péricart; David Grand; Nadia Amara; Frédéric Escudié; Julia Gilhodes; Pierre Bories; Alexandra Traverse-Glehen; Romain Dubois; Pierre Brousset; Marie Parrens; Camille Laurent Journal: Haematologica Date: 2018-10-11 Impact factor: 9.941
Authors: Daniel P Cassidy; Jennifer R Chapman; Rafael Lopez; Kyle White; Yao-Shan Fan; Carmen Casas; Eric A Severson; Francisco Vega Journal: Am J Clin Pathol Date: 2020-02-08 Impact factor: 2.493
Authors: Daniel J Landsburg; Marissa K Falkiewicz; Joseph Maly; Kristie A Blum; Christina Howlett; Tatyana Feldman; Anthony R Mato; Brian T Hill; Shaoying Li; L Jeffrey Medeiros; Pallawi Torka; Francisco Hernandez-Ilizaliturri; Nishitha M Reddy; Arun Singavi; Timothy S Fenske; Julio C Chavez; Jason B Kaplan; Amir Behdad; Adam M Petrich; Martin A Bast; Julie M Vose; Adam J Olszewski; Cristiana Costa; Frederick Lansigan; James N Gerson; Stefan K Barta; Oscar Calzada; Jonathon B Cohen; Jennifer K Lue; Jennifer E Amengual; Xavier Rivera; Daniel O Persky; David J Peace; Sunita Nathan; Ryan D Cassaday Journal: J Clin Oncol Date: 2017-05-05 Impact factor: 44.544
Authors: Mehdi Hamadani; John Radford; Carmelo Carlo-Stella; Paolo F Caimi; Erin Reid; Owen A O'Connor; Jay M Feingold; Kirit M Ardeshna; William Townsend; Melhem Solh; Leonard T Heffner; David Ungar; Luqiang Wang; Joseph Boni; Karin Havenith; Yajuan Qin; Brad S Kahl Journal: Blood Date: 2021-05-13 Impact factor: 22.113